(Q33434260)

English

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

prostate cancer

1 reference

based on heuristic

inferred from title

Joan Carles Galcerán

object named as

Joan Carles

2

0 references

Silke Gillessen

object named as

Silke Gillessen

3

0 references

1

object named as

Fred Saad

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Axel Heidenreich

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Daniel Heinrich

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jeremy Gratt

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jérémy Lévy

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kurt Miller

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sten Nilsson

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Oana Petrenciuc

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Marcello Tucci

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Manfred Wirth

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Judith Federhofer

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Joe M O'Sullivan

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Radium-223 International Early Access Program Investigators

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

26 July 2016

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1306-1316

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Pain predicts overall survival in men with metastatic castration-refractory prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimal management of metastatic castration-resistant prostate cancer: highlights from a European Expert Consensus Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone in metastatic prostate cancer without previous chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased survival with enzalutamide in prostate cancer after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Enzalutamide in metastatic prostate cancer before chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha emitter radium-223 and survival in metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Revision of the NIST Standard for (223)Ra: New Measurements and Review of 2008 Data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting bone metastases in prostate cancer: improving clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, [...]

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2816%2930173-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(16)30173-5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33434260&oldid=1663291931"